Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Anand Devaraj et al.|The Lancet Respiratory Medicine|2020Cited by 558
Early detection of lung cancer by using an autoantibody panel in Chinese populationShengxiang Ren, Fred R. Hirsch, Shucai Zhang et al.|OncoImmunology|2017Cited by 203